CryoPort Inc (CYRX)

[H2R]

Hi CYRXorbust

Since it's a subscription site, I won't cut&paste his entire article, but I hope it's OK if I do this section on BMY:

The developing relationship with Bristol-Myers Squibb and the two other big pharma companies is of importance beyond that of the immediate dollars. BMY is pursuing multiple drug platforms in immune-oncology and gene therapy treatments, among others, and it seems logical to think that they will turn to Cryoport to support the logistics for products requiring shipment at cryogenic temperature. The same can be said for Genzyme and Janssen. Cryoport believes that its logistics platform could also provide cost-effective support for pharmaceutical such as monoclonal antibodies that require cold chain distribution, but not cryogenic logistics. If this were to happen, it might be a major opportunity.

Cryoport has given no guidance on how to model sales for these relationships so I can only guess at how much they might contribute. I am guessing that they are somewhere between $250,000 (top end of guidance for a phase 3 product) and $2 million (low end of guidance for a commercial product. This leads me to estimate that peak sales at three years (2020) will be roughly $800,000 each for Bristol-Myers Squibb, Sanofi and Johnson & Johnson. The resultant combined revenues are $200,000 in 2018, $800,000 in 2019 and $1.6 million in 2020.

(bold mine)

Regards